Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Silence Therapeutics Plc ADR (SLN)

Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Silence Therapeutics Plc ADR 72 HAMMERSMITH ROAD LONDON X0 W14 8TH GBR

www.silence-therapeutics.com P: 44-0-20-3457-6900

Description:

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.

Key Statistics

Overview:

Market Capitalization, $K 686,548
Enterprise Value, $K 619,338
Shares Outstanding, K 29,928
Annual Sales, $ 31,560 K
Annual Net Income, $ -53,820 K
Last Quarter Sales, $ 2,810 K
Last Quarter Net Income, $ -17,960 K
EBIT, $ -61,710 K
EBITDA, $ -61,090 K
60-Month Beta 1.38
% of Insider Shareholders 2.95%
% of Institutional Shareholders 98.73%
Float, K 29,045
% Float 97.05%
Short Volume Ratio 0.32

Growth:

1-Year Return 322.02%
3-Year Return -9.41%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.47 on 03/13/24
Latest Earnings Date 05/21/24 [--]
Earnings Per Share ttm -1.46
EPS Growth vs. Prev Qtr -67.86%
EPS Growth vs. Prev Year -2.17%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SLN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -262.18%
Return-on-Assets % -45.62%
Profit Margin % -170.53%
Debt/Equity 0.00
Price/Sales 21.18
Price/Cash Flow N/A
Price/Book 29.83
Book Value/Share 0.71
Interest Coverage -22.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar